Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 3 Randomized, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Tegoprubart Compared With Tacrolimus in Adult Participants Undergoing De Novo Kidney Transplantation

NCT07835581 is registered in ClinicalTrials.gov with Eledon Pharmaceuticals as lead sponsor.

NCT NCT07835581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07835581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 3 Randomized, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Tegoprubart Compared With Tacrolimus in Adult Participants Undergoing De Novo Kidney Transplantation
Lead sponsor
Eledon Pharmaceuticals
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
March 31, 2033
Enrollment
620 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant rejection